Vetoquinol Shares Dip at Close After Hitting Record High
Vetoquinol experienced a mixed session on Monday, February 2, 2026. After setting a new annual high at €88.50, the animal health specialist closed down 2.3% at €84.80. This volatility comes amid positively revised analyst expectations.
Market Performance of Vetoquinol
This Monday, Vetoquinol's stock market journey exemplifies investor nervousness following a recent strong rally. The veterinary laboratory reached a new record high at the opening, marking the culmination of a sustained upward trend over several weeks. However, this level quickly triggered profit-taking, bringing the price below its previous resistance threshold now set at €86.90.
Technical analysis still reveals a fundamentally strong trend. The stock is significantly above its moving averages, with a 5.6% gap from the MM50 established at €80.23 and 11.1% from the MM200 at €76.43. The RSI stands at 55, indicating a satisfactory balance between buyers and sellers, far from overheated zones. This positioning suggests that the potential for progress remains intact despite the day's decline.
Revised Analyst Expectations
On January 30, the analysis firm Portzamparc hardened its stance on the stock, adopting a 'strengthen' recommendation with a raised target price from €85 to €91. This new target offers a potential appreciation of 7.2% compared to the last quoted price, which reinforces the positive visibility of the group in its segment.
This improvement in expectations is part of a remarkable twelve-month stock market journey, with the stock showing an annual performance of 19.58%. Over a shorter horizon, the growth remains robust with a gain of 13.81% over three months, confirming the persistent interest of investors in this specialist whose sector exposure remains favorable. The moderate volatility of 5.28% over a month and an almost zero beta (0.02) further underline the relative stability of the stock against market fluctuations.
